Utilizing this model in ER+ breast cancer patients could help to identify which patients are likely to favorably respond to CDK4/6 inhibition and which patients will probably have intrinsic resistance, and therefore should take a different course of treatment. Here, ESR1 is linked to breast carcinoma.